OPK-88005 is under clinical development by OPKO Health and currently in Phase I for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase I drugs for Hemophilia A (Factor VIII Deficiency) have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OPK-88005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OPK-88005 (Factor VIIa-CTP) is under development for the treatment of bleeding episodes in hemophilia A and B patients. It is administered intravenously and subcutaneously as every-other-day prophylactic treatment or twice a week regimen. It is a long acting factor VIIa fused to carboxyl terminal peptide (FVIIa-CTP).
OPKO Health overview
OPKO Health (OPKO) discovers, develops, manufactures, and commercializes novel diagnostic technologies and pharmaceuticals products. The company’s product portfolio includes 4K score test used for diagnosis of prostate cancer; Rayaldee (calcifediol), an extended-release capsule for treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease; and the Claros analyzer, a blood performance test. OPKO develops products using proprietary technologies including, Carboxyl Terminal Peptide (CTP) technology, Reversible PEGylation and AntagoNAT technology. It is advancing pipeline products targeted for the treatment of hypophosphatemia, obesity, diabetes, haemophilia, growth hormone deficiency, dravet syndrome and other diseases. It also offers veterinary products. The company has operational presence with offices located in Chile, Mexico, Spain, Ireland, Canada, and Israel. OPKO is headquartered in Miami, Florida, the US.
For a complete picture of OPK-88005’s drug-specific PTSR and LoA scores, buy the report here.